Turning on cGMP-dependent pathways to treat cardiac dysfunctions: Boom, bust, and beyond

Trends in Pharmacological Sciences

Volumn 35, Issue 8, 2014, Pages 404-413

  Lukowski, Robert ^a   Krieg, Thomas ^b   Rybalkin, Sergei D ^c   Beavo, Joseph ^c   Hofmann, Franz ^d  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

cardiomyopathy; cGMP dependent protein kinase type I; guanylyl cyclases; nitric oxide; phosphodiesterase 5; protein kinase G

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CINACIGUAT; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE 1; GUANYLATE CYCLASE; NATRIURETIC PEPTIDE TYPE C; NESIRITIDE; PHOSPHODIESTERASE I; PHOSPHODIESTERASE III; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; RIOCIGUAT; SILDENAFIL; SPLEEN EXONUCLEASE; TADALAFIL; URODILATIN;

ACUTE HEART FAILURE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); DIASTOLIC HEART FAILURE; DISEASE MODEL; DRUG FATALITY; DRUG MECHANISM; DRUG SCREENING; DRUG TARGETING; DUCHENNE MUSCULAR DYSTROPHY; ENZYME INHIBITION; ERECTILE DYSFUNCTION; GENETIC MANIPULATION; HEART FAILURE; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE OVERLOAD; HUMAN; MULTICENTER STUDY (TOPIC); NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; SYSTOLIC HEART FAILURE;

CARDIOMYOPATHY; CGMP-DEPENDENT PROTEIN KINASE TYPE I; GUANYLYL CYCLASES; NITRIC OXIDE; PHOSPHODIESTERASE 5; PROTEIN KINASE G;

ANIMALS; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; HEART DISEASES; HUMANS; PHOSPHODIESTERASE 5 INHIBITORS;

EID: 84905456735     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2014.05.003     Document Type: Review

References (101)

1. R. Lukowski et al. Cardiac hypertrophy is not amplified by deletion of cGMP-dependent protein kinase I in cardiomyocytes Proc. Natl. Acad. Sci. U.S.A. 107 2010 5646 5651
2. C. Methner et al. Protection through postconditioning or a mitochondria-targeted S-nitrosothiol is unaffected by cardiomyocyte-selective ablation of protein kinase G Basic Res. Cardiol. 108 2013 337
3. S. Frantz et al. Stress-dependent dilated cardiomyopathy in mice with cardiomyocyte-restricted inactivation of cyclic GMP-dependent protein kinase I Eur. Heart J. 34 2013 1233 1244
4. M. Klaiber et al. A cardiac pathway of cyclic GMP-independent signaling of guanylyl cyclase A, the receptor for atrial natriuretic peptide Proc. Natl. Acad. Sci. U.S.A. 108 2011 18500 18505
5. R.M. Blanton et al. Protein kinase Giα inhibits pressure overload-induced cardiac remodeling and is required for the cardioprotective effect of sildenafil in vivo J. Am. Heart Assoc. 1 2012 e003731
6. M. Guazzi et al. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study Circ. Heart Fail. 4 2011 8 17
7. L. van Heerebeek et al. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction Circulation 126 2012 830 839
8. M.M. Redfield et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial J. Am. Med. Assoc. 309 2013 1268 1277
9. M.J. Andersen et al. Sildenafil and diastolic dysfunction after acute myocardial infarction in patients with preserved ejection fraction: the Sildenafil and Diastolic Dysfunction After Acute Myocardial Infarction (SIDAMI) trial Circulation 127 2013 1200 1208
10. C.M. Adamo et al. Sildenafil reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy Proc. Natl. Acad. Sci. U.S.A. 107 2010 19079 19083
11. J.M. Percival et al. Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy J. Pathol. 228 2012 77 87
12. C.F. Deschepper Cardioprotective actions of cyclic GMP: lessons from genetic animal models Hypertension 55 2010 453 458
13. D. Garcia-Dorado et al. Myocardial protection against reperfusion injury: the cGMP pathway Thromb. Haemost. 101 2009 635 642
14. D.A. Kass et al. Phosphodiesterase type 5: expanding roles in cardiovascular regulation Circ. Res. 101 2007 1084 1095
15. L.R. Potter et al. Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications Handb. Exp. Pharmacol. 191 2009 341 366
16. E.R. Derbyshire, and M.A. Marletta Biochemistry of soluble guanylate cyclase Handb. Exp. Pharmacol. 191 2009 17 31
17. F. Hofmann The biology of cyclic GMP-dependent protein kinases J. Biol. Chem. 280 2005 1 4
18. M. Conti, and J. Beavo Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling Annu. Rev. Biochem. 76 2007 481 511
19. R. Worner et al. cGMP signals mainly through cAMP kinase in permeabilized murine aorta Am. J. Physiol. Heart Circ. Physiol. 292 2007 H237 H244
20. M. Movsesian, and R. Kukreja Phosphodiesterase inhibition in heart failure S.H. Francis, Phosphodiesterases as Drug Targets 2011 Springer 237 249
21. S.D. Rybalkin et al. Cyclic GMP phosphodiesterases and regulation of smooth muscle function Circ. Res. 93 2003 280 291
22. T. Ecker et al. Decreased cardiac concentration of cGMP kinase in hypertensive animals. An index for cardiac vascularization? Circ. Res. 65 1989 1361 1369
23. L.R. Potter et al. Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications Handb. Exp. Pharmacol. 2009 341 366
24. M.J. Lopez et al. Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide Nature 378 1995 65 68
25. P.M. Oliver et al. Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A Proc. Natl. Acad. Sci. U.S.A. 94 1997 14730 14735
26. R. Holtwick et al. Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A J. Clin. Invest. 111 2003 1399 1407
27. I. Kishimoto et al. A genetic model provides evidence that the receptor for atrial natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular myocyte hypertrophy Proc. Natl. Acad. Sci. U.S.A. 98 2001 2703 2706
28. M. Volpe et al. Natriuretic peptides in cardiovascular diseases: current use and perspectives Eur. Heart J. 35 2014 419 425
29. S.J. Greene et al. The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction J. Am. Heart Assoc. 2 2013 e000536
30. W.S. Colucci et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group N. Engl. J. Med. 343 2000 246 253
31. C.M. O'Connor et al. Effect of nesiritide in patients with acute decompensated heart failure N. Engl. J. Med. 365 2011 32 43
32. D.M. Dickey et al. Guanylyl cyclase (GC)-A and GC-B activities in ventricles and cardiomyocytes from failed and non-failed human hearts: GC-A is inactive in the failed cardiomyocyte J. Mol. Cell. Cardiol. 52 2012 727 732
33. K.R. Gotz et al. Transgenic mice for real-time visualization of cGMP in intact adult cardiomyocytes Circ. Res. 114 2014 1235 1245
34. S.J. Sangaralingham et al. The aging heart, myocardial fibrosis, and its relationship to circulating C-type natriuretic peptide Hypertension 57 2011 201 207
35. Y. Izumiya et al. Chronic C-type natriuretic peptide infusion attenuates angiotensin II-induced myocardial superoxide production and cardiac remodeling Int. J. Vasc. Med. 2012 2012 246058
36. T. Soeki et al. C-type natriuretic peptide, a novel antifibrotic and antihypertrophic agent, prevents cardiac remodeling after myocardial infarction J. Am. Coll. Cardiol. 45 2005 608 616
37. A. Hobbs et al. Natriuretic peptide receptor-C regulates coronary blood flow and prevents myocardial ischemia/reperfusion injury: novel cardioprotective role for endothelium-derived C-type natriuretic peptide Circulation 110 2004 1231 1235
38. A. Kilic et al. A novel chimeric natriuretic peptide reduces cardiomyocyte hypertrophy through the NHE-1-calcineurin pathway Cardiovasc. Res. 88 2010 434 442
39. F.L. Martin et al. CD-NP: a novel engineered dual guanylyl cyclase activator with anti-fibrotic actions in the heart PLoS ONE 7 2012 e52422
40. J.S. Bice et al. NO-independent stimulation or activation of soluble guanylyl cyclase during early reperfusion limits infarct size Cardiovasc. Res. 101 2014 220 228
41. F.N. Salloum et al. Cinaciguat, a novel activator of soluble guanylate cyclase, protects against ischemia/reperfusion injury: role of hydrogen sulfide Am. J. Physiol. Heart Circ. Physiol. 302 2012 H1347 H1354
42. T. Krieg et al. BAY 58-2667, a nitric oxide-independent guanylyl cyclase activator, pharmacologically post-conditions rabbit and rat hearts Eur. Heart J. 30 2009 1607 1613
43. J.C. Irvine et al. The soluble guanylyl cyclase activator BAY 58-2667 selectively limits cardiomyocyte hypertrophy PLoS ONE 7 2012 e44481
44. D. Groneberg et al. Cell-specific deletion of nitric oxide-sensitive guanylyl cyclase reveals a dual pathway for nitrergic neuromuscular transmission in the murine fundus Gastroenterology 145 2013 188 196
45. D. Groneberg et al. Smooth muscle-specific deletion of nitric oxide-sensitive guanylyl cyclase is sufficient to induce hypertension in mice Circulation 121 2010 401 409
46. A. Friebe et al. Fatal gastrointestinal obstruction and hypertension in mice lacking nitric oxide-sensitive guanylyl cyclase Proc. Natl. Acad. Sci. U.S.A. 104 2007 7699 7704
47. J. Erdmann et al. Dysfunctional nitric oxide signalling increases risk of myocardial infarction Nature 504 2013 432 436
48. E. Erdmann et al. Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure Eur. Heart J. 34 2013 57 67
49. A. Pfeifer et al. Defective smooth muscle regulation in cGMP kinase I-deficient mice EMBO J. 17 1998 3045 3051
50. S.K. Michael et al. High blood pressure arising from a defect in vascular function Proc. Natl. Acad. Sci. U.S.A. 105 2008 6702 6707
51. R.M. Blanton et al. Mutation of the protein kinase I alpha leucine zipper domain produces hypertension and progressive left ventricular hypertrophy: a novel mouse model of age-dependent hypertensive heart disease J. Gerontol. A: Biol. Sci. Med. Sci. 68 2013 1351 1355
52. D.C. Guo et al. Recurrent gain-of-function mutation in PRKG1 causes thoracic aortic aneurysms and acute aortic dissections Am. J. Hum. Genet. 93 2013 398 404
53. S. Weber et al. Rescue of cGMP kinase I knockout mice by smooth muscle specific expression of either isozyme Circ. Res. 101 2007 1096 1103
54. F. Loga et al. The role of cGMP/cGKI signalling and Trpc channels in regulation of vascular tone Cardiovasc. Res. 100 2013 280 287
55. E. Patrucco et al. cGMP kinase I, cardiac hypertrophy and PDE inhibition BMC Pharmacol. 11 Suppl. 1 2011 O19
56. V. Leiss et al. Cyclic GMP kinase I modulates glucagon release from pancreatic alpha-cells Diabetes 60 2011 148 156
57. M. Foller et al. Anemia and splenomegaly in cGKI-deficient mice Proc. Natl. Acad. Sci. U.S.A. 105 2008 6771 6776
58. E. Takimoto et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy Nat. Med. 11 2005 214 222
59. M. Klaiber et al. Novel insights into the mechanisms mediating the local antihypertrophic effects of cardiac atrial natriuretic peptide: role of cGMP-dependent protein kinase and RGS2 Basic Res. Cardiol. 105 2010 583 595
60. E. Takimoto et al. Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice J. Clin. Invest. 119 2009 408 420
61. E. Takimoto et al. cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism Circ. Res. 96 2005 100 109
62. S. Hsu et al. Phosphodiesterase 5 inhibition blocks pressure overload-induced cardiac hypertrophy independent of the calcineurin pathway Cardiovasc. Res. 81 2009 301 309
63. J. Nagendran et al. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility Circulation 116 2007 238 248
64. R.C. Kukreja et al. Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection J. Am. Coll. Cardiol. 59 2012 1921 1927
65. A. Das et al. ERK phosphorylation mediates sildenafil-induced myocardial protection against ischemia-reperfusion injury in mice Am. J. Physiol. Heart Circ. Physiol. 296 2009 H1236 H1243
66. M. Madhani et al. Phospholemman Ser69 phosphorylation contributes to sildenafil-induced cardioprotection against reperfusion injury Am. J. Physiol. Heart Circ. Physiol. 299 2010 H827 H836
67. S. Koka et al. Phosphodiesterase-5 inhibitor tadalafil attenuates oxidative stress and protects against myocardial ischemia/reperfusion injury in type 2 diabetic mice Free Radic. Biol. Med. 60 2013 80 88
68. N. Koitabashi et al. Cyclic GMP/PKG-dependent inhibition of TRPC6 channel activity and expression negatively regulates cardiomyocyte NFAT activation. Novel mechanism of cardiac stress modulation by PDE5 inhibition J. Mol. Cell. Cardiol. 48 2010 713 724
69. M. Nishida et al. Phosphorylation of TRPC6 channels at Thr69 is required for anti-hypertrophic effects of phosphodiesterase 5 inhibition J. Biol. Chem. 285 2010 13244 13253
70. E. Takimoto et al. Compartmentalization of cardiac beta-adrenergic inotropy modulation by phosphodiesterase type 5 Circulation 115 2007 2159 2167
71. M. Zaccolo, and M.A. Movsesian cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology Circ. Res. 100 2007 1569 1578
72. S.D. Rybalkin et al. Differential effects of PDE5 inhibitors on cardiac dysfunction in the MDX [m]ouse model of Duchenne muscular dystrophy BMC Pharmacol. Toxicol. 14 Suppl. 1 2013 O38
73. P. Pokreisz et al. Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice Circulation 119 2009 408 416
74. X. Shan et al. Differential expression of PDE5 in failing and nonfailing human myocardium Circ. Heart Fail. 5 2012 79 86
75. M. Zhang et al. Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes Cell. Signal. 20 2008 2231 2236
76. F. Vandeput et al. cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium J. Pharmacol. Exp. Ther. 330 2009 884 891
77. F.N. Salloum et al. Phosphodiesterase-5 inhibitor, tadalafil, protects against myocardial ischemia/reperfusion through protein-kinase G-dependent generation of hydrogen sulfide Circulation 120 2009 S31 S36
78. Z. Jin et al. The beneficial effects of tadalafil on left ventricular dysfunction in doxorubicin-induced cardiomyopathy J. Cardiol. 62 2013 110 116
79. M. Wehling-Henricks et al. Cardiomyopathy in dystrophin-deficient hearts is prevented by expression of a neuronal nitric oxide synthase transgene in the myocardium Hum. Mol. Genet. 14 2005 1921 1933
80. M. Khairallah et al. Sildenafil and cardiomyocyte-specific cGMP signaling prevent cardiomyopathic changes associated with dystrophin deficiency Proc. Natl. Acad. Sci. U.S.A. 105 2008 7028 7033
81. Y. Burelle et al. Alterations in mitochondrial function as a harbinger of cardiomyopathy: lessons from the dystrophic heart J. Mol. Cell. Cardiol. 48 2010 310 321
82. R.J. Barst et al. Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management Circulation 125 2012 113 122
83. R.C. Santos et al. Tadalafil-induced improvement in left ventricular diastolic function in resistant hypertension Eur. J. Clin. Pharmacol. 70 2014 147 154
84. J.W. Elrod et al. Sildenafil-mediated acute cardioprotection is independent of the NO/cGMP pathway Am. J. Physiol. Heart Circ. Physiol. 292 2007 H342 H347
85. C.L. Miller et al. Cyclic nucleotide phosphodiesterase 1A: a key regulator of cardiac fibroblast activation and extracellular matrix remodeling in the heart Basic Res. Cardiol. 106 2011 1023 1039
86. 2+/calmodulin-stimulated cyclic nucleotide phosphodiesterase 1 in mediating cardiomyocyte hypertrophy Circ. Res. 105 2009 956 964
87. R.T. MacFarland et al. High concentrations of a cGMP-stimulated phosphodiesterase mediate ANP-induced decreases in cAMP and steroidogenesis in adrenal glomerulosa cells J. Biol. Chem. 266 1991 136 142
88. H. Mehel et al. Phosphodiesterase-2 is up-regulated in human failing hearts and blunts beta-adrenergic responses in cardiomyocytes J. Am. Coll. Cardiol. 62 2013 1596 1606
89. L.R. Moltzau et al. Differential regulation of C-type natriuretic peptide-induced cGMP and functional responses by PDE2 and PDE3 in failing myocardium Naunyn Schmiedeberg Arch. Pharmacol. 387 2014 407 417
90. O. Prysyazhna et al. Single atom substitution in mouse protein kinase G eliminates oxidant sensing to cause hypertension Nat. Med. 18 2012 286 290
91. Dostmann, W. et al. The University of Vermont and State Agricultural College. Novel peptidic activators of type I cGMP dependent protein kinases and uses thereof, US20140037547
92. L.R. Castro et al. Feedback control through cGMP-dependent protein kinase contributes to differential regulation and compartmentation of cGMP in rat cardiac myocytes Circ. Res. 107 2010 1232 1240
93. W. Mokni et al. Concerted regulation of cGMP and cAMP phosphodiesterases in early cardiac hypertrophy induced by angiotensin II PLoS ONE 5 2010 e14227
94. M. Thunemann et al. Transgenic mice for cGMP imaging Circ. Res. 113 2013 365 371
95. L.W. Nausch et al. Differential patterning of cGMP in vascular smooth muscle cells revealed by single GFP-linked biosensors Proc. Natl. Acad. Sci. U.S.A. 105 2008 365 370
96. S. Korkmaz et al. Pharmacological activation of soluble guanylate cyclase protects the heart against ischemic injury Circulation 120 2009 677 686
97. M.V. Cohen et al. Cardioprotective PKG-independent NO signaling at reperfusion Am. J. Physiol. Heart Circ. Physiol. 299 2010 H2028 H2036
98. C. Methner et al. Riociguat reduces infarct size and post-infarct heart failure in mouse hearts: insights from MRI/PET imaging PLoS ONE 8 2013 e83910
99. S. Geschka et al. Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats PLoS ONE 6 2011 e21853
100. J. Schroter et al. Homologous desensitization of guanylyl cyclase A, the receptor for atrial natriuretic peptide, is associated with a complex phosphorylation pattern FEBS J. 277 2010 2440 2453
101. P.M. Bryan, and L.R. Potter The atrial natriuretic peptide receptor (NPR-A/GC-A) is dephosphorylated by distinct microcystin-sensitive and magnesium-dependent protein phosphatases J. Biol. Chem. 277 2002 16041 16047